Skip to main content
AMGN
NASDAQ Life Sciences

AstraZeneca-Amgen Combo Hits Survival Goal in Lung Cancer Trial

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$411.91
Mkt Cap
$236.381B
52W Low
$269.77
52W High
$447.03
52W Position info
53% above low
Off High info
7.9% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

AMGN sits 53% above its 52-week low of $269.77.

Summary

AstraZeneca's Imfinzi combined with Amgen's Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial. This is a major positive for Amgen's oncology franchise, as Imdelltra is a key growth asset. The result validates the combination strategy and could expand the drug's market opportunity. Amgen shares are likely to react favorably to this news, especially given recent pressure from the Novartis trial failure. Watch for detailed data presentation at an upcoming medical conference.

Updates

  1. · Reuters — The combo also improved progression-free survival and response rate with no new safety concerns. Imdelltra alone brought in $513 million last year.

At the time of this announcement, AMGN was trading at $411.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $236.4B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $458.60 info
Change: -$18.80 (-4%) info
Market Cap: $248.842B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $458.60 info
Change: -$6.32 (-1%) info
Market Cap: $248.842B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $458.60 info
Change: -$4.40 (-0.95%) info
Market Cap: $248.842B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $458.60 info
Change: -$1.97 (-0.43%) info
Market Cap: $248.842B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $458.60 info
Change: +$9.81 (+2%) info
Market Cap: $248.842B info